AR012576A1 - Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina, procedimiento para su preparacion, composiciones que los comprenden, procedimiento para preparar dichas composiciones y el uso de dichos derivados para la fabricacion de un medicamento - Google Patents

Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina, procedimiento para su preparacion, composiciones que los comprenden, procedimiento para preparar dichas composiciones y el uso de dichos derivados para la fabricacion de un medicamento

Info

Publication number
AR012576A1
AR012576A1 ARP980101598A ARP980101598A AR012576A1 AR 012576 A1 AR012576 A1 AR 012576A1 AR P980101598 A ARP980101598 A AR P980101598A AR P980101598 A ARP980101598 A AR P980101598A AR 012576 A1 AR012576 A1 AR 012576A1
Authority
AR
Argentina
Prior art keywords
hydrogen
procedure
alkyl
derivatives
compositions
Prior art date
Application number
ARP980101598A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR012576A1 publication Critical patent/AR012576A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto de la formula (I), una forma N-oxido, las sales de adicion farmacéuticamente aceptables y sus formas estereoquímicamente isoméricas donde:cada R1 es independientemente hidrogeno, halogeno, alquilo C1-6, nitro, hidroxi o alquiloxi C1- 4; alc es alcanodiilo C1-6; n es 1 o 2; D es 1- o 2-benzimidazolilo, 2(3H)benzoxazolona-3-ilo o un radical de las formulas (a), (b), (c), (d), (e), (f), (g); donde cada X independientemente representa O, So NR12; R12 es hidrogeno, alquilo C1-6,a rilo o arilalquilo de C1-6; R3 es hidrogeno, alquilo C1-6, alquiloxi C1-6, alquitio C1-6, amino o mono- o di(alquilo C1-6)amino, R4, R5, R6, R7, R8, R9, R10, R11 y R12 son cada uno independientemente hidrogeno o alquilo C1-6; R9 eshidrog eno, alquilo o ariloC1-6; o R3 y R4 tomados juntos pueden formar un radical bivalente -R3-R4 de la formula: -CH2CH2-CH2 (a1); -CH2CH2-CH2-CH2 (a2); CH=CH-CH2- (a3); -CH2-CH=CH-(a4) o -CH=CH-CH=CH (a5); donde uno o dos átomos de hidrogeno dedichos radicales (a1) hasta (a5) cada uno independientemente pueden ser reemplazadospor halo, alquilo C1-6, arilalquilo C1-6, trifluorometilo, amino, hidroxi, alquiloxi C1-6 o alquilcarboniloxi C1-10; o cuando se posible, dos átomos dehidrogenogeminal pueden ser reemplazados por alquilideno C1-6 o arilalquilideno C1-6; o -R3-R4- pueden ser: -S-CH2-CH2 (a6); -S-CH2-CH2-CH2-(a7); -S-CH=CH- (a8); -NH-CH2-CH2- (a9); -NH-CH2-CH2-CH2- (a10); -NH-CH=CH- (a11); -NH-CH=N- (a12);-S-CH=N- (a13) o -CH=CH0-O- (a14) donde uno o cuando esposible dos o tres átomos de hidrogeno en dichos radicales (a6) hasta (a14) cada uno independientemente pueden ser reemplazados por alquilo o arilo C1-6; yaril es fenilo o fenilo sustituidoc on halo o alquilo C1-6. Tienen una actividad antagonista de los receptores adrenérgicos alfa2. Además de refiere
ARP980101598A 1997-04-08 1998-04-07 Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina, procedimiento para su preparacion, composiciones que los comprenden, procedimiento para preparar dichas composiciones y el uso de dichos derivados para la fabricacion de un medicamento AR012576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201045 1997-04-08

Publications (1)

Publication Number Publication Date
AR012576A1 true AR012576A1 (es) 2000-11-08

Family

ID=8228191

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101598A AR012576A1 (es) 1997-04-08 1998-04-07 Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina, procedimiento para su preparacion, composiciones que los comprenden, procedimiento para preparar dichas composiciones y el uso de dichos derivados para la fabricacion de un medicamento

Country Status (31)

Country Link
US (1) US6156757A (es)
EP (1) EP1019408B1 (es)
JP (1) JP3287577B2 (es)
KR (1) KR100315975B1 (es)
CN (1) CN1097053C (es)
AP (1) AP1138A (es)
AR (1) AR012576A1 (es)
AT (1) ATE270294T1 (es)
AU (1) AU727599B2 (es)
BG (1) BG63848B1 (es)
BR (1) BR9806263A (es)
CA (1) CA2264598C (es)
CZ (1) CZ290008B6 (es)
DE (1) DE69824872T2 (es)
EE (1) EE03691B1 (es)
ES (1) ES2224391T3 (es)
GE (1) GEP20022823B (es)
HU (1) HUP0003624A3 (es)
ID (1) ID22131A (es)
IL (1) IL128701A0 (es)
MY (1) MY120033A (es)
NO (1) NO322826B1 (es)
NZ (1) NZ334501A (es)
PL (1) PL189549B1 (es)
RU (1) RU2198175C2 (es)
SK (1) SK283621B6 (es)
TR (1) TR199900644T2 (es)
TW (1) TW589315B (es)
UA (1) UA52681C2 (es)
WO (1) WO1998045297A1 (es)
ZA (1) ZA982969B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
CN1131868C (zh) 1998-10-06 2003-12-24 詹森药业有限公司 作为药物的三环△3-哌啶
ID28967A (id) * 1998-12-21 2001-07-19 Janssen Pharmaceutica Nv Benzisoksazol dan fenon sebagai alfa 2-antagonis
CA2451606A1 (en) 2001-07-05 2003-01-16 Pharmacia & Upjohn Company (hetero) aryl substituted benzofurans as 5-ht ligands
CA2480266C (en) * 2002-04-03 2011-07-12 Orion Corporation Use of an alpha2-adrenoreceptor antagonist for cns-related diseases
MXPA05003607A (es) * 2002-10-04 2005-11-17 Prana Biotechnology Ltd Compuestos neurologicamente activos.
CN1972938B (zh) 2004-04-12 2010-09-29 大正制药株式会社 环状胺化合物
EP2077262A4 (en) * 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVES AND THEIR USE
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
ES2478823T3 (es) * 2008-04-23 2014-07-23 Takeda Pharmaceutical Company Limited Derivados de iminopiridina y uso de los mismos
US8575186B2 (en) * 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
EP2668191A4 (en) 2011-01-19 2014-08-20 Albany Molecular Res Inc BENZOFURO- [3,2-C-] PYRIDINES AND RELATED ANALOGS AS SEROTONIN-SUBTYPE-6 (5-HT6) MODULATORS FOR THE TREATMENT OF ADIPOSITAS, METABOLISM SYNDROME, COGNITION AND SCHIZOPHRENIA
GB201704325D0 (en) * 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
US4686226A (en) * 1985-09-03 1987-08-11 Merck & Co., Inc. Substituted benzo[b]furo- and benzo[b]thieno quinolizines
US4985422A (en) * 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі

Also Published As

Publication number Publication date
US6156757A (en) 2000-12-05
AP9901650A0 (en) 1999-09-30
PL189549B1 (pl) 2005-08-31
NO322826B1 (no) 2006-12-11
GEP20022823B (en) 2002-10-25
BR9806263A (pt) 2000-04-04
MY120033A (en) 2005-08-30
TR199900644T2 (xx) 2000-09-21
DE69824872D1 (de) 2004-08-05
ID22131A (id) 1999-09-09
JP3287577B2 (ja) 2002-06-04
CN1237179A (zh) 1999-12-01
TW589315B (en) 2004-06-01
CA2264598A1 (en) 1998-10-15
EP1019408B1 (en) 2004-06-30
SK283621B6 (sk) 2003-10-07
ES2224391T3 (es) 2005-03-01
HUP0003624A2 (hu) 2001-04-28
NO990859L (no) 1999-09-30
AP1138A (en) 2003-01-17
IL128701A0 (en) 2000-01-31
AU7430798A (en) 1998-10-30
CN1097053C (zh) 2002-12-25
JP2000505115A (ja) 2000-04-25
WO1998045297A1 (en) 1998-10-15
CA2264598C (en) 2006-10-24
HUP0003624A3 (en) 2002-09-30
BG63848B1 (bg) 2003-03-31
ATE270294T1 (de) 2004-07-15
CZ68299A3 (cs) 2000-08-16
CZ290008B6 (cs) 2002-05-15
NZ334501A (en) 2000-06-23
DE69824872T2 (de) 2005-09-01
KR100315975B1 (ko) 2001-12-22
RU2198175C2 (ru) 2003-02-10
EP1019408A1 (en) 2000-07-19
KR20000036076A (ko) 2000-06-26
PL332382A1 (en) 1999-09-13
BG103213A (en) 2000-05-31
EE03691B1 (et) 2002-04-15
ZA982969B (en) 1999-10-07
AU727599B2 (en) 2000-12-14
UA52681C2 (uk) 2003-01-15
EE9900114A (et) 1999-12-15
NO990859D0 (no) 1999-02-23
SK28799A3 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
AR012576A1 (es) Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina, procedimiento para su preparacion, composiciones que los comprenden, procedimiento para preparar dichas composiciones y el uso de dichos derivados para la fabricacion de un medicamento
DE60330910D1 (de) Verbindungen mit selektiverinhibierender wirkung für gsk3
PA8654801A1 (es) Tratamiento para la tuberculosis latente
PE20200665A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
YU48105B (sh) Derivati triazola i postupak za njihovo dobijanje
ES8101072A1 (es) Un procedimiento para la preparacion de nuevas benzamidas sustituidas
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR069326A1 (es) Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia.
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
ES2623982T3 (es) Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada
HRP20070194T3 (en) N-thiazol-2-yl-benzamide derivatives
ITRM20010465A1 (it) Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
ES530901A0 (es) Procedimiento para preparar derivados de piperazina
KR930703319A (ko) 키산틴 유도체
DE69003200D1 (de) Arylsubstituierte Aminderivate verwendbar in der Krebstherapie.
PE20030447A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
AR034174A1 (es) Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
CA2331141A1 (en) Water soluble azoles as broad-spectrum antifungals
CO5160261A1 (es) Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması
ES2052593T3 (es) Procedimiento para preparar derivados del indano.
CO5640050A2 (es) Nuevos derivados de anilina, su elaboracion y uso como agentes farmaceuticos

Legal Events

Date Code Title Description
FG Grant, registration